Medical Crossfire® Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Welcome and Introductions

Module 1: Assessing Risk in Patients with Early-Stage HR+, HER2- Breast Cancer

Module 2: Incorporating CDK4/6 Inhibitors in Regimens for Early HR+ Breast Cancer

Module 3: Managing the Patient with High-Risk gBRCA-Mutated HR+/HER2- Early-Stage Breast Cancer

Module 4: Is There a Role for Immune Checkpoint Inhibitors in Early-Stage HR+, HER2- Breast Cancer?

Module 5: Future Directions for High-Risk HR+, HER2- Breast Cancers